Related Experiment Videos
Suspected opioid overdose case resolved by CYP2D6 genotyping
Kaitlyn D Shaw1, Ursula Amstutz, Ricardo Jimenez-Mendez
1Division of Translational Therapeutics, Department of Paediatrics, Faculty of Medicine, University of British Columbia, Canada.
Therapeutic Drug Monitoring
|March 13, 2012
Summary
Genetic testing for CYP2D6 was performed on a teen with suspected opiate overdose. This highlights the importance of pharmacogenetics in tailoring pain management and opioid drug therapy.
Area of Science:
- Pharmacogenetics
- Clinical Pharmacology
- Toxicology
Background:
- The management of suspected narcotic overdose requires accurate identification of the causative agent.
- Pharmacogenetics, the study of genetic variations influencing drug response, plays a crucial role in optimizing pharmacotherapy.
Observation:
- A 14-year-old female presented with symptoms suggestive of a narcotic overdose.
- CYP2D6 genotyping was conducted to investigate potential opiate intoxication.
Findings:
- CYP2D6 genotyping can aid in verifying opiate intoxication in clinical toxicology cases.
- Understanding individual genetic profiles, such as CYP2D6 variants, is essential for personalized pain management.
Implications:
- Pharmacogenetic testing can inform clinical decisions regarding opioid pharmacotherapy.
- Individualizing pain management strategies based on genetic factors may improve treatment efficacy and safety.
- This case underscores the utility of pharmacogenetics in both overdose situations and routine pain management.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...